

**Amendments to the Claims**

Please cancel Claims 98-163. Please amend Claims 1, 2, 8-15, 17, 18, 20, 25-31, 33, 34, 36, 39-46, 48, 49, 51, 54-60, 62, 63, 65, 70-77, 79, 80, 82, 87-93, 95, and 96. The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

1. (Currently Amended) A method of inhibiting the interaction of a cell bearing mammalian CC- chemokine receptor 1 (CCR1) with a ligand thereof, comprising contacting said cell with ~~an effective amount of~~ an antibody or antigen-binding fragment thereof which binds to mammalian CC-chemokine receptor 1 (CCR1) or portion of said receptor comprising the second extracellular loop and inhibits binding of said ligand to the receptor, wherein said antibody or antigen-binding fragment thereof binds the second extracellular loop of said receptor.
2. (Currently Amended) A method according to Claim 1, wherein the cell is selected from the group consisting of lymphocytes, monocytes, granulocytes, neutrophils, T cells, basophils, and cells comprising a recombinant nucleic acid encoding CCR1 or a portion thereof comprising the second extracellular loop.
3. (Original) A method according to Claim 2, wherein the cell is a T cell selected from the group consisting of CD26+ cells and CD45RO+ cells.
4. (Original) A method according to Claim 1, wherein said antibody or antigen-binding fragment thereof inhibits one or more functions associated with binding of the ligand to said receptor.
5. (Original) A method according to Claim 1, wherein said mammalian CC-chemokine receptor 1 is a human CC-chemokine receptor 1.

6. (Original) A method according to Claim 1, wherein the ligand is a chemokine.
7. (Original) A method according to Claim 6, wherein the chemokine is any one or more of MIP-1 $\alpha$ , RANTES, MCP-2, MCP-3, leukotactin-1, HCC-1 or MPIF.
8. (Currently Amended) A method according to Claim 1, wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of:
  - a) monoclonal antibody 2D4;
  - b) antigen-binding fragments of (a) which bind to mammalian CC-chemokine receptor 1 (CCR1) or a portion thereof comprising the second extracellular loop; and
  - c) combinations of the foregoing.
9. (Currently Amended) A method according to Claim 1, wherein said antibody or antigen-binding fragment is a monoclonal antibody or antigen-binding fragment thereof.
10. (Currently Amended) A method according to Claim 1, wherein said antibody or antigen-binding fragment is a chimeric antibody or antigen-binding fragment thereof.
11. (Currently Amended) A method according to Claim 1, wherein said antibody or antigen-binding fragment is a human antibody or antigen-binding fragment thereof.
12. (Currently Amended) A method according to Claim 1, wherein said antibody or antigen-binding fragment is a humanized antibody or antigen-binding fragment thereof.
13. (Currently Amended) A method according to Claim 12, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more antigen-binding regions of monoclonal antibody 2D4.

14. (Currently Amended) A method according to Claim 12, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.
15. (Currently Amended) A method according to Claim 14, wherein said humanized antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.
16. (Original) A method according to Claim 1, wherein said antibody or antigen-binding fragment is a recombinant antibody or antigen-binding fragment thereof.
17. (Currently Amended) A method according to Claim 16, wherein said recombinant antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.
18. (Currently Amended) A method according to Claim 17, wherein said recombinant antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.
19. (Original) A method according to Claim 1, wherein said antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an F(ab')<sub>2</sub> fragment.
20. (Currently Amended) A method of inhibiting the interaction of a cell bearing mammalian CC- chemokine receptor 1 (CCR1) with a ligand thereof, comprising contacting said cell with ~~an effective amount of~~ an antibody or antigen-binding fragment thereof which binds to mammalian CC-chemokine receptor 1 (CCR1) ~~or portion of said receptor~~ and inhibits binding of said ligand to the receptor, wherein said antibody or antigen-binding fragment thereof can compete with monoclonal antibody 2D4 for binding to said receptor.

21. (Original) A method according to Claim 20, wherein said antibody or antigen-binding fragment thereof inhibits one or more functions associated with binding of the ligand to said receptor.
22. (Original) A method according to Claim 20, wherein said mammalian CC-chemokine receptor 1 is a human CC-chemokine receptor 1.
23. (Original) A method according to Claim 20, wherein the ligand is a chemokine.
24. (Original) A method according to Claim 23, wherein the chemokine is selected from the group consisting of MIP-1 $\alpha$ , RANTES, MCP-2, MCP-3, leukotactin-1, HCC-1 and MIPF.
25. (Currently Amended) A method according to Claim 20, wherein said antibody or antigen-binding fragment is a monoclonal antibody or antigen-binding fragment thereof.
26. (Currently Amended) A method according to Claim 20, wherein said antibody or antigen-binding fragment is a chimeric antibody or antigen-binding fragment thereof.
27. (Currently Amended) A method according to Claim 20, wherein said antibody or antigen-binding fragment is a human antibody or antigen-binding fragment thereof.
28. (Currently Amended) A method according to Claim 20, wherein said antibody or antigen-binding fragment is a humanized antibody or antigen-binding fragment thereof.
29. (Currently Amended) A method according to Claim 28, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more antigen-binding regions of monoclonal antibody 2D4.

30. (Currently Amended) A method according to Claim 28, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.
31. (Currently Amended) A method according to Claim 30, wherein said humanized antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.
32. (Original) A method according to Claim 20, wherein said antibody or antigen-binding fragment is a recombinant antibody or antigen-binding fragment thereof.
33. (Currently Amended) A method according to Claim 32, wherein said recombinant antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.
34. (Currently Amended) A method according to Claim 33, wherein said recombinant antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.
35. (Original) A method according to Claim 20, wherein said antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an F(ab')<sub>2</sub> fragment.
36. (Currently Amended) A method of inhibiting a function associated with binding of a chemokine to a mammalian CC-chemokine receptor 1 (CCR1) or a functional portion of said receptor, comprising contacting a composition comprising the receptor or functional portion thereof with ~~an effective amount of~~ an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 1 (CCR1) or portion of said receptor comprising the second extracellular loop, wherein said antibody or fragment inhibits binding of said chemokine to mammalian CC-chemokine receptor 1 (CCR1) and

inhibits one or more functions associated with binding of the chemokine to the receptor, and wherein said antibody or antigen-binding fragment thereof binds the second extracellular loop of said receptor.

37. (Original) A method according to Claim 36, wherein the chemokine is any one or more of MIP-1 $\alpha$ , RANTES, MCP-2, MCP-3, leukotactin-1, HCC-1 or MPIF.
38. (Original) A method according to Claim 36, wherein said mammalian CC-chemokine receptor 1 is a human CC-chemokine receptor 1.
39. (Currently Amended) A method according to Claim 36, wherein the antibody or antigen-binding fragment is selected from the group consisting of:
  - a) monoclonal antibody 2D4;
  - b) antigen-binding fragments of (a) which bind to mammalian CC-chemokine receptor 1 (CCR1) or a portion thereof comprising the second extracellular loop; and
  - c) combinations of the foregoing.
40. (Currently Amended) A method according to Claim 36, wherein said antibody or antigen-binding fragment is a monoclonal antibody or antigen-binding fragment thereof.
41. (Currently Amended) A method according to Claim 36, wherein said antibody or antigen-binding fragment is a chimeric antibody or antigen-binding fragment thereof.
42. (Currently Amended) A method according to Claim 36, wherein said antibody or antigen-binding fragment is a human antibody or antigen-binding fragment thereof.
43. (Currently Amended) A method according to Claim 36, wherein said antibody or antigen-binding fragment is a humanized antibody or antigen-binding fragment thereof.

44. (Currently Amended) A method according to Claim 43, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more antigen-binding regions of monoclonal antibody 2D4.
45. (Currently Amended) A method according to Claim 43, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.
46. (Currently Amended) A method according to Claim 45, wherein said humanized antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.
47. (Original) A method according to Claim 36, wherein said antibody or antigen-binding fragment is a recombinant antibody or antigen-binding fragment thereof.
48. (Currently Amended) A method according to Claim 47, wherein said recombinant antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.
49. (Currently Amended) A method according to Claim 48, wherein said recombinant antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.
50. (Original) A method according to Claim 36, wherein said antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an F(ab')<sub>2</sub> fragment.
51. (Currently Amended) A method of inhibiting a function associated with binding of a chemokine to a mammalian CC-chemokine receptor 1 (CCR1) or a functional portion of said receptor, comprising contacting a composition comprising the receptor or functional

portion thereof with ~~an effective amount of~~ an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 1 (CCR1) ~~or portion of said receptor~~, wherein said antibody or fragment inhibits binding of said chemokine to mammalian CC-chemokine receptor 1 (CCR1) and inhibits one or more functions associated with binding of the chemokine to the receptor, and wherein said antibody or antigen-binding fragment thereof can compete with monoclonal antibody 2D4 for binding to said receptor.

52. (Original) A method according to Claim 51, wherein said mammalian CC-chemokine receptor 1 is a human CC-chemokine receptor 1.
53. (Original) A method according to Claim 51, wherein the chemokine is selected from the group consisting of MIP-1 $\alpha$ , RANTES, MCP-2, MCP-3, leukotactin-1, HCC-1 and MPIF.
54. (Currently Amended) A method according to Claim 51, wherein said antibody or antigen-binding fragment is a monoclonal antibody or antigen-binding fragment thereof.
55. (Currently Amended) A method according to Claim 51, wherein said antibody or antigen-binding fragment is a chimeric antibody or antigen-binding fragment thereof.
56. (Currently Amended) A method according to Claim 51, wherein said antibody or antigen-binding fragment is a human antibody or antigen-binding fragment thereof.
57. (Currently Amended) A method according to Claim 51, wherein said antibody or antigen-binding fragment is a humanized antibody or antigen-binding fragment thereof.
58. (Currently Amended) A method according to Claim 57, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more antigen-binding regions of monoclonal antibody 2D4.



59. (Currently Amended) A method according to Claim 57, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.
60. (Currently Amended) A method according to Claim 59, wherein said humanized antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.
61. (Original) A method according to Claim 51, wherein said antibody or antigen-binding fragment is a recombinant antibody or antigen-binding fragment thereof.
62. (Currently Amended) A method according to Claim 61, wherein said recombinant antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.
63. (Currently Amended) A method according to Claim 62, wherein said recombinant antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.
64. (Original) A method according to Claim 51, wherein said antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an F(ab')<sub>2</sub> fragment.
65. (Currently Amended) A method of inhibiting leukocyte trafficking in a patient, comprising administering to the patient a composition comprising ~~an effective amount of~~ an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 1 (CCR1) or portion of said receptor comprising the second extracellular loop and inhibits binding of a ligand to the receptor, wherein said antibody or antigen-binding fragment thereof binds the second extracellular loop of said receptor.

66. (Original) A method according to Claim 65, wherein said antibody or antigen-binding fragment thereof inhibits one or more functions associated with binding of the ligand to said receptor.
67. (Original) A method according to Claim 65, wherein said mammalian CC-chemokine receptor 1 is a human CC-chemokine receptor 1.
68. (Original) A method according to Claim 65, wherein the ligand is a chemokine.
69. (Original) A method according to Claim 68, wherein the chemokine is any one or more of MIP-1 $\alpha$ , RANTES, MCP-2, MCP-3, leukotactin-1, HCC-1 or MPIF.
70. (Currently Amended) A method according to Claim 65, wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of:
- a) monoclonal antibody 2D4;
  - b) antigen-binding fragments of (a) which bind to mammalian CC-chemokine receptor 1 (CCR1) or a portion thereof comprising the second extracellular loop; and
  - c) combinations of the foregoing.
71. (Currently Amended) A method according to Claim 65, wherein said antibody or antigen-binding fragment is a monoclonal antibody or antigen-binding fragment thereof.
72. (Currently Amended) A method according to Claim 65, wherein said antibody or antigen-binding fragment is a chimeric antibody or antigen-binding fragment thereof.
73. (Currently Amended) A method according to Claim 65, wherein said antibody or antigen-binding fragment is a human antibody or antigen-binding fragment thereof.

74. (Currently Amended) A method according to Claim 65, wherein said antibody or antigen-binding fragment is a humanized antibody or antigen-binding fragment thereof.
75. (Currently Amended) A method according to Claim 74, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more antigen-binding regions of monoclonal antibody 2D4.
76. (Currently Amended) A method according to Claim 74, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.
77. (Currently Amended) A method according to Claim 76, wherein said humanized antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.
78. (Original) A method according to Claim 65, wherein said antibody or antigen-binding fragment is a recombinant antibody or antigen-binding fragment thereof.
79. (Currently Amended) A method according to Claim 78, wherein said recombinant antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.
80. (Currently Amended) A method according to Claim 79, wherein said recombinant antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.
81. (Original) A method according to Claim 65, wherein said antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an F(ab')<sub>2</sub> fragment.

82. (Currently Amended) A method of inhibiting leukocyte trafficking in a patient, comprising administering to the patient a composition comprising ~~an effective amount of~~ an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 1 (CCR1) ~~or portion of said receptor~~ and inhibits binding of a ligand to the receptor, wherein said antibody or antigen-binding fragment thereof can compete with monoclonal antibody 2D4 for binding to said receptor.
83. (Original) A method according to Claim 82, wherein said antibody or antigen-binding fragment thereof inhibits one or more functions associated with binding of the ligand to said receptor.
84. (Original) A method according to Claim 82, wherein said mammalian CC-chemokine receptor 1 is a human CC-chemokine receptor 1.
85. (Original) A method according to Claim 82, wherein the ligand is a chemokine.
86. (Original) A method according to Claim 85, wherein the chemokine is selected from the group consisting of MIP-1 $\alpha$ , RANTES, MCP-2, MCP-3, leukotactin-1, HCC-1 and MPIF.
87. (Currently Amended) A method according to Claim 82, wherein said antibody or antigen-binding fragment is a monoclonal antibody or antigen-binding fragment thereof.
88. (Currently Amended) A method according to Claim 82, wherein said antibody or antigen-binding fragment is a chimeric antibody or antigen-binding fragment thereof.
89. (Currently Amended) A method according to Claim 82, wherein said antibody or antigen-binding fragment is a human antibody or antigen-binding fragment thereof.

90. (Currently Amended) A method according to Claim 82, wherein said antibody or antigen-binding fragment is a humanized antibody or antigen-binding fragment thereof.
91. (Currently Amended) A method according to Claim 90, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more antigen-binding regions of monoclonal antibody 2D4.
92. (Currently Amended) A method according to Claim 90, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.
93. (Currently Amended) A method according to Claim 92, wherein said humanized antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.
94. (Original) A method according to Claim 82, wherein said antibody or antigen-binding fragment is a recombinant antibody or antigen-binding fragment thereof.
95. (Currently Amended) A method according to Claim 94, wherein said recombinant antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.
96. (Currently Amended) A method according to Claim 95, wherein said recombinant antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.
97. (Original) A method according to Claim 82, wherein said antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an F(ab')<sub>2</sub> fragment.

Claims 98-163 (Cancelled)